BSG and UKPBC primary biliary cholangitis treatment and management guidelines

Under review

Abstract

Primary biliary cholangitis (formerly known as primary biliary cirrhosis, PBC) is an autoimmune liver disease in which a cycle of immune mediated biliary epithelial cell injury, cholestasis and progressive fibrosis can culminate over time in an end-stage biliary cirrhosis. Both genetic and environmental influences are presumed relevant to disease initiation. PBC is most prevalent in women and those over the age of 50, but a spectrum of disease is recognised in adult patients globally; male sex, younger age at onset (<45) and advanced disease at presentation are baseline predictors of poorer outcome. As the disease is increasingly diagnosed through the combination of cholestatic serum liver tests and the presence of antimitochondrial antibodies, most presenting patients are not cirrhotic and the term cholangitis is more accurate. Disease course is frequently accompanied by symptoms that can be burdensome for patients, and management of patients with PBC must address, in a life-long manner, both disease progression and symptom burden. Licensed therapies include ursodeoxycholic acid (UDCA) and obeticholic acid (OCA), alongside experimental new and re-purposed agents. Disease management focuses on initiation of UDCA for all patients and risk stratification based on baseline and on-treatment factors, including in particular the response to treatment. Those intolerant of treatment with UDCA or those with high-risk disease as evidenced by UDCA treatment failure (frequently reflected in trial and clinical practice as an alkaline phosphatase >1.67 × upper limit of normal and/or elevated bilirubin) should be considered for second-line therapy, of which OCA is the only currently licensed National Institute for Health and Care Excellence recommended agent. Follow-up of patients is life-long and must address treatment of the disease and management of associated symptoms.

Read More

BSG logo
Clinical Resources Categories
BSG Nurses Association
Inflammatory Bowel Disease
Practice recommendations for midwives caring for women and birthing people living with inflammatory bowel disease
clinical-resource/Practice-recommendations-for-midwives
The following practice recommendations were developed to standardise the midwifery care given to women and birthing people living with IBD during pregnancy.

BSG logo
Guidance
Colorectal
BSG/ACPGBI guidance on the management of colorectal polyps in patients with limited life expectancy
clinical-resource/Management-of-colorectal-polyps-in-patients
This BSG and ACPGBI guidance aims to help clinicians and patients consider these risks to aid decision-making for polypectomy versus a conservative approach.